News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
493,001 Results
Type
Article (8920)
Company Profile (142)
Press Release (483500)
Multimedia
Podcasts (5)
Webinars (6)
Section
Business (169082)
Career Advice (345)
Deals (26039)
Drug Delivery (8)
Drug Development (53688)
Employer Resources (16)
FDA (9908)
Job Trends (8742)
News (241656)
Policy (18362)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (562)
Accelerated approval (26)
ADA (22)
Adcomms (3)
Allergies (99)
Alliances (33644)
ALS (105)
Alzheimer's disease (1000)
Antibody-drug conjugate (ADC) (277)
Approvals (10527)
Artificial intelligence (330)
ASCO (159)
Autoimmune disease (210)
Automation (29)
Bankruptcy (265)
Best Places to Work (7068)
BIO (37)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (113)
BioSpace Insights (20)
Biotechnology (90)
Bladder cancer (151)
Brain cancer (32)
Breast cancer (525)
Cancer (3765)
Cardiovascular disease (225)
Career advice (278)
Career pathing (2)
CAR-T (175)
CDC (4)
CDMO (9)
Celiac Disease (1)
Cell therapy (483)
Cervical cancer (35)
Clinical research (48604)
Collaboration (1274)
Commercialization (3)
Company closure (1)
Compensation (1483)
Complete response letters (34)
COVID-19 (833)
CRISPR (64)
C-suite (776)
Cystic fibrosis (86)
Data (5798)
Denatured (5)
Depression (104)
Dermatology (64)
Diabetes (351)
Diagnostics (4259)
Digital health (39)
Diversity (2)
Diversity, equity & inclusion (5)
Drug discovery (158)
Drug pricing (13)
Drug shortages (2)
Duchenne muscular dystrophy (167)
Earnings (74086)
Editorial (4)
Employer branding (2)
Employer resources (16)
Events (88829)
Executive appointments (727)
FDA (12591)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (958)
Gene editing (129)
Generative AI (12)
Gene therapy (328)
GLP-1 (304)
Government (1066)
Grass and pollen (2)
Guidances (283)
Healthcare (9699)
Hematology (94)
HIV (58)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (99)
Immuno-oncology (60)
Indications (157)
Infectious disease (1023)
Inflammatory bowel disease (129)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (259)
Interviews (42)
IPO (12503)
IRA (4)
Job creations (2021)
Job search strategy (259)
JPM (3)
Kidney cancer (16)
Labor market (1)
Layoffs (68)
Leadership (1)
Legal (5290)
Licensing (11)
Liver cancer (48)
Longevity (18)
Lung cancer (519)
Lymphoma (256)
Machine learning (30)
Management (4)
Manufacturing (550)
Marketing (8)
MASH (120)
Medical device (8787)
Medtech (8940)
Mergers & acquisitions (14568)
Metabolic disorders (726)
mRNA (62)
Multiple sclerosis (104)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (41)
Neuroscience (1863)
NextGen: Class of 2026 (3293)
Non-profit (1052)
Now hiring (1)
Obesity (234)
Opinion (24)
Ovarian cancer (163)
Pain (175)
Pancreatic cancer (202)
Parkinson's disease (202)
Partnered (12)
Patents (488)
Patient recruitment (520)
Peanut (31)
People (42154)
Pharmaceutical (30)
Pharmacy benefit managers (10)
Phase 1 (15635)
Phase 2 (21714)
Phase 3 (14717)
Pipeline (7529)
Policy (29)
Postmarket research (1609)
Preclinical (6612)
Press Release (34)
Prostate cancer (196)
Psychedelics (10)
Radiopharmaceuticals (194)
Rare diseases (590)
Real estate (3151)
Recruiting (6)
Regulatory (15132)
Reports (21)
Research institute (644)
Resumes & cover letters (58)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (101)
Series A (161)
Series B (125)
Service/supplier (5)
Sickle cell disease (63)
Special edition (2)
Spinal muscular atrophy (88)
Sponsored (6)
Startups (2085)
Stomach cancer (4)
Supply chain (52)
Vaccines (349)
Venture capital (18)
Weight loss (78)
Women's health (84)
Date
Today (119)
Last 7 days (324)
Last 30 days (1625)
Last 365 days (19289)
2026 (12900)
2025 (19462)
2024 (23262)
2023 (26773)
2022 (34915)
2021 (37622)
2020 (34035)
2019 (24112)
2018 (18164)
2017 (19122)
2016 (18322)
2015 (24689)
2014 (22002)
2013 (18450)
2012 (20503)
2011 (20798)
2010 (20565)
Location
Africa (253)
Alabama (75)
Alaska (2)
Arizona (309)
Arkansas (11)
Asia (18638)
Australia (2199)
California (12147)
Canada (3190)
China (540)
Colorado (490)
Connecticut (417)
Delaware (208)
Europe (26330)
Florida (1831)
Georgia (389)
Hawaii (3)
Idaho (47)
Illinois (716)
India (52)
Indiana (322)
Iowa (15)
Japan (412)
Kansas (102)
Kentucky (32)
Louisiana (27)
Maine (27)
Maryland (1228)
Massachusetts (7960)
Michigan (311)
Minnesota (578)
Mississippi (5)
Missouri (84)
Montana (20)
Nebraska (11)
Nevada (121)
New Hampshire (60)
New Jersey (2728)
New Mexico (13)
New York (2871)
North Carolina (1338)
North Dakota (4)
Northern California (6088)
Ohio (286)
Oklahoma (15)
Oregon (19)
Pennsylvania (2278)
Puerto Rico (20)
Rhode Island (32)
South America (452)
South Carolina (78)
South Dakota (1)
Southern California (5046)
Tennessee (128)
Texas (1973)
United States (39608)
Utah (364)
Vermont (1)
Virginia (161)
Washington D.C. (40)
Washington State (944)
West Virginia (2)
Wisconsin (76)
Wyoming (1)
493,001 Results for "hill rom inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow
Oak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.
July 28, 2026
·
2 min read
·
Tristan Manalac
Opinion
Why pediatric rare oncology outperforms in a volatile biotech market
Real progress happens where unmet medical need is greatest and patient impact can be clearly measured. Pediatric rare cancers exemplify these criteria and have therefore generated continued investment, even in a capital-constrained environment.
August 20, 2026
·
5 min read
·
Paul Romness
Press Releases
Octapharma to build $1.5 billion state-of-the-art critical care manufacturing facility in Rock Hill, SC
July 29, 2026
·
3 min read
Press Releases
Oak Hill Bio Announces Dosing of First Participant in BEACON Phase 3 Clinical Trial of Rugonersen in Angelman Syndrome
July 28, 2026
·
5 min read
Press Releases
Canadian Dermatology Association in Partnership with Melanoma Canada Offer Free Skin Cancer Screenings on Parliament Hill
May 27, 2026
·
4 min read
Press Releases
Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome
July 27, 2026
·
16 min read
Press Releases
Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome
June 1, 2026
·
5 min read
Press Releases
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
June 30, 2026
·
7 min read
Press Releases
Lung Cancer Survivors and Advocates Head to Capitol Hill to Champion Lifesaving Research, Prevention and Access to Care
March 23, 2026
·
3 min read
Biosenta Announces Engagement of Oak Hill Financial Inc.
Biosenta Inc. (CSE: ZRO) (“Biosenta” or the “Company”) announces that it has entered into an agreement with Oak Hill Financial Inc. (“Oak Hill”) to provide business
January 11, 2024
·
3 min read
1 of 49,301
Next
